An overview of cyclophosphamide and ifosfamide pharmacology

Pharmacotherapy

Volumn 17, Issue 5 II SUPPL., 1997, Pages

  Fleming, Ronald A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IFOSFAMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER; CONFERENCE PAPER; DRUG DNA INTERACTION; HUMAN; LEUKOPENIA; NEUROTOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; HUMANS; IFOSFAMIDE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0030765658     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963;105:574-8.
2. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy. JAMA 1946;132:126-32.
3. Brock N. Oxazaphosphorine cytostatics: past-present-future. Cancer Res 1989;49:1-7.
4. Gomeri G. Histochemical demonstration of sites of phosphamidase activity. Proc Soc Exp Biol Med 1948;69: 407-10.
5. Hilton J. Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide-sensitive and resistant L1210 cells. Biochem Pharmacol 1984;33:1867-72.
6. Tew KD, Colvin M, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy. Philadelphia: Lippincott-Raven, 1996:297-332.
7. 31P Nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites. J Med Chem 1986;29:1206-10.
8. Little SA, Mirkes PE. DNA cross-linking and single-strand breaks induced by teratogenic concentrations of 4-hydroperoxycyclophosphamide and phosphoramide mustard in postimplantation rat embryos. Cancer Res 1987;47:5421-6.
9. Nathanson L, Hall TC, Rutenberg A, Shadduck RK. Clinical toxicologic study of cyclohexylamine salt of N,N-bis(2-chloroethyl)phosphorodiamidic acid. Cancer Chemother Rep 1967;51:35-9.
10. Vendrik CPJ, Bergers JJ, Dejong WH, Steerenberg PA. Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 1992;29:413-29.
11. Tew KD, Houghton PJ, Houghton JA. Preclinical and clinical modulation of anticancer drugs. Boca Raton, FL: CRC Press, 1993:13-77.
12. Bunting KD, Townsend AJ. De novo expression of transfected human class 1 aldehyde dehydrogenase causes resistance to oxazaphosphorine anticancer alkylating agents in hamster V79 cell lines. J Biol Chem 1996;271:11884-90.
13. von Eitzen U, Meier-Tackmann D, Agawal DP, Goedde HW. Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes. Cancer Lett 1994;76:45-9.
14. McNiel NO, Morgan LR. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. Int J Clin Pharmacol Ther Toxicol 1981;19:490-3.
15. Wagner T, Drings P. Pharmacokinetics and bioavailability of oral ifosfamide. Arzneimittelforschung 1986;36:878-80.
16. Wagner T, Feneberg K. Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations. Arzneimittelforschung 1984;34:313-16.
17. Moore M. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991;20:194-208.
18. Wagner T. Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 1994;26:439-56.
19. Bagley CM, Bostick FW, DeVita VT. Clinical pharmacology of cyclophosphamide. Cancer Res 1973;33:226-33.
20. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-37.
21. Walker D, Flinois JP, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and dechloroethylation of ifosfamide. Biochem Pharmacol 1994;47:1157-63.
22. Wagner T, Heydrich D, Jork T, Voelcker G, Hohorst HJ. Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol 1981;100:95-104.
23. Allen LM, Creaven PJ, Nelson RL. Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat Rep 1976;60:451-8.
24. Lewis LD. Ifosfamide pharmacokinetics. Invest New Drugs 1991;9:305-11.
25. Lewis LD, Fitzgerald DL, Mohan P, Thatcher N, Harper PG, Rogers HJ. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol 1991;31:77-82.
26. Chen TL, Passos-Coelho JL, Noe DA, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995;55:810-16.
27. Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484-94.
28. Juma FD, Rogers HJ, Trounce JR. The pharmacokinetics of cyclophosphamide, phosphoramide mustard, and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 1980;10: 327-35.
29. Phillipou G, Seaborn CJ, Raniolo E. Reproducibility of methods relating to cyclophosphamide studies. J Natl Cancer Inst 1993;85:1249-50.
30. Norpoth K. Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat Rep 1976;437-43.
31. Hadidi AFA, Coulter CEA, Idle JR. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res 1988;48:5167-71.
32. Juma FD. Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol 1984;26:591-3.
33. Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981;19:443-51.
34. Mouridsen HT, Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 1975;36:409-14.
35. Wang LH, Lee CS, Majeske BL, Marbury TC. Clearance and recovery calculations in hemodialysis: application to plasma, red blood cell, and dialysate measurements for cyclophosphamide. Clin Pharmacol Ther 1981;29:365-72.
36. Wagner VT, Heydrich D, Bartels H, Hohorst HJ. Einflub von leberparenchymschaden, niereninsuffizienz und hamodialyse auf die pharmakokinetik von cyclophosphamid und seinen aktivierten metaboliten. Arzneim Forschung 1980;30:1588-92.
37. Powis G, Reece P, Ahmann DL, Ingle JN. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 1987;20:219-22.
38. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 1989;25:139-42.
39. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM. The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol 1990;30:140-3.
40. Boddy AV, Furtan Y, Sardas S, Sardas O, Idle JR. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J Natl Cancer Inst 1992;84:1744-8.
41. Yoshida A. Molecular genetics of human aldehyde dehydrogenase. Pharmacogenetics 1992;2:139-47.
42. Dockham PA, Lee MO, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992;43:2453-69.
43. Dorr RT, Von Hoff DD. Cancer chemotherapy handbook. East Norwalk, CT: Appleton & Lange, 1994:319-32.
44. Jao JY, Jusko WJ, Cohen JL. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res 1972;32:2761-4.
45. Faber OK, Mouridsen HT, Skovsted L. The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man. Br J Clin Pharmacol 1975;2:281-5.
46. Moore MJ, Hardy RW, Thiessen JJ, Soldin SJ, Erlichman C. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 1988;44:622-8.
47. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995-1000.
48. Clamon GH. Alkylating agents. In: Perry MC, ed. The chemotherapy sourcebook. Baltimore: Williams & Wilkins, 1992:286-300.
49. Yarbo JW, Bornstein RS, Mastrangelo MJ, eds. Clinical applications of alkylating agents. Semin Oncol 1996;23(suppl 6):1-116.
50. Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991;9:2016-20.
51. Vose JM, Reed EC, Pippert GC, et al. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 1993;11:1306-10.
52. Brock N, Stekar J, Pohl J, Neimeyer U, Scheffler G. Acrolein, the causative factor of urotoxic side effects of cyclophosphamide, ifosfamide, trophosphamide and sufosfamide. Arzneim Forschung 1979;29:659-61.
53. Cox PJ. Cyclophosphamide cystitis - identification of acrolein as the causative agent. Biochem Pharmacol 1979;28:2045-9.
54. DeFronzo RA, Braine H, Colvin OM, Davis PJ. Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation. Ann Intern Med 1973;78:861-9.
55. Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985;145:548-9.
56. Goren MP, Pratt CB, Viar MJ. Tubular nephrotoxicity during long-term ifosfamide and mesna therapy. Cancer Chemother Pharmacol 1989;25:70-2.
57. Goren MP, Wright RK, Pratt CB, Pell FE. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986;2:1219-20.
58. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986;22:815-19.